Stocks Health care JNJ
NYSE · Health careJohnson & Johnson (JNJ)
Johnson & Johnson brought in $97.9B of revenue over the twelve months to June 28, 2026, up 8.1% from a year earlier. Net income was $21B, a net margin of 21.5%. Operating cash flow minus capital spending left $19.7B of free cash flow in fiscal 2025. At June 28, 2026 it held $20.4B in cash against $37.3B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 23, 2026.
What Johnson & Johnson does
Johnson & Johnson researches, develops, and manufactures prescription pharmaceuticals and medical devices. Its products include medicines for immunology, oncology, and infectious diseases, as well as surgical instruments and orthopedic implants. These are sold to hospitals, physicians, and pharmacies. The company is known for medical technology and healthcare products. Its shares trade on NYSE under the ticker JNJ.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $94.2B | $26.8B | $11.03 | $19.7B |
| 2024 | $88.8B | $14.1B | $5.79 | $19.8B |
| 2023 | $85.2B | $35.2B | $13.72 | $18.2B |
| 2022 | $80B | $17.9B | $6.73 | $17.2B |
| 2021 | $78.7B | $20.9B | $7.81 | $19.8B |
| 2020 | $82.6B | $14.7B | $5.51 | $20.2B |
Latest SEC filings
What Johnson & Johnson has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 11, 2026Form N-PX filing N-PX
- August 6, 2026Form 13F-HR filing 13F-HR
- August 4, 2026
- July 29, 2026
- July 28, 2026
- July 23, 2026Quarterly report 10-Q · period to June 28, 2026
- July 15, 2026
- June 25, 2026
- June 25, 2026
- May 27, 2026
Questions about JNJ
What does Johnson & Johnson do?
Johnson & Johnson researches, develops, and manufactures prescription pharmaceuticals and medical devices. Its products include medicines for immunology, oncology, and infectious diseases, as well as surgical instruments and orthopedic implants. These are sold to hospitals, physicians, and pharmacies. The company is known for medical technology and healthcare products. Its shares trade on NYSE under the ticker JNJ.
Is Johnson & Johnson profitable?
Yes. Over the twelve months to June 28, 2026 it reported net income of $21B on revenue of $97.9B, a net margin of 21.5%.
How much revenue does Johnson & Johnson make?
Over the twelve months to June 28, 2026 Johnson & Johnson reported revenue of $97.9B. That is 8.1% more than a year earlier.
When did Johnson & Johnson last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 23, 2026. It covers the period to June 28, 2026. Its newest filing of any kind is the insider trade from September 10, 2026.
Similar companies
Follow JNJ
Get an email when Johnson & Johnson files with the SEC: results, executive changes, material agreements and annual reports.
Follow JNJ: get an email when it filesWhere the numbers come from
Financial figures are the values Johnson & Johnson tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.